Serveur d'exploration Tocilizumab - Curation (Istex)

Index « AbsEn.i » - entrée « results »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
resulting < results < retardation  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 211.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000009 (2008) Misato Hashizume [Japon] ; Masahiko Mihara [Japon]Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling
000014 (2012) Seiji Ohtori [Japon] ; Masayuki Miyagi [Japon] ; Yawara Eguchi [Japon] ; Gen Inoue [Japon] ; Sumihisa Orita [Japon] ; Nobuyasu Ochiai [Japon] ; Shunji Kishida [Japon] ; Kazuki Kuniyoshi [Japon] ; Junichi Nakamura [Japon] ; Yasuchika Aoki [Japon] ; Tetsuhiro Ishikawa [Japon] ; Gen Arai [Japon] ; Hiroto Kamoda [Japon] ; Miyako Suzuki [Japon] ; Masashi Takaso [Japon] ; Takeo Furuya [Japon] ; Gou Kubota [Japon] ; Yoshihiro Sakuma [Japon] ; Yasuhiro Oikawa [Japon] ; Tomoaki Toyone [Japon] ; Kazuhisa Takahashi [Japon]Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica
000016 (2009) Mao Mao An [République populaire de Chine] ; Zui Zou [République populaire de Chine] ; Hui Shen [République populaire de Chine] ; Jun Dong Zhang [République populaire de Chine] ; Yong Bing Cao [République populaire de Chine] ; Yuan Ying Jiang [République populaire de Chine]The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials
000025 (2014) Shuji Ohta [Japon] ; Tomomi Tsuru [Japon] ; Kimio Terao [Japon] ; Seiji Mogi [Japon] ; Midori Suzaki [Japon] ; Eisuke Shono [Japon] ; Yoshimasa Ishida [Japon] ; Eriko Tarumi [Japon] ; Masato Imai [Japon]Mechanism‐based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)
000031 (2005) Shumpei Yokota [Japon] ; Takako Miyamae [Japon] ; Tomoyuki Imagawa [Japon] ; Shigeki Katakura [Japon] ; Rumiko Kurosawa [Japon] ; Masaaki Mori [Japon]Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis
000035 (2013) T. Witte [Allemagne]Methotrexat als Kombinationspartner bei TNF-Inhibitoren und Tocilizumab
000038 (2016) Tristan Pascart [France, Niger] ; Peggy Philippe [France] ; Elodie Drumez [France] ; Xavier Deprez [France] ; Bernard Cortet [France] ; Alain Duhamel [France] ; Eric Houvenagel [France] ; René-Marc Flipo [France]Comparative efficacy of tocilizumab, abatacept and rituximab after non‐TNF inhibitor failure: results from a multicentre study
000039 (2011) Toshio Tanaka [Japon] ; Keisuke Hagihara [Japon] ; Yoshihito Shima [Japon] ; Masashi Narazaki [Japon] ; Atsushi Ogata [Japon] ; Atsushi Kumanogoh [Japon]Tocilizumab, a humanized anti‐interleukin‐6 receptor antibody, for the treatment of autoimmune disorders
000066 (2013) Kanae Tani [Japon] ; Risa Takayanagi [Japon] ; Haruko Yokoyama [Japon] ; Yasuhiko Yamada [Japon]Theoretical analysis of efficacy of biological agent for rheumatoid arthritis based on target molecular binding occupancy
000087 (2011) K. Krüger [Allemagne] ; B. Hellmich [Allemagne] ; A. Rubbert-Roth [Allemagne] ; U. Müller-Ladner [Allemagne] ; A. Kielhorn [Allemagne]Ist der Vergleich verschiedener Studien zur Wirksamkeit von Biologika bei Patienten mit rheumatoider Arthritis möglich?
000088 (2011) Emily Beth Devine [États-Unis] ; Rafael Alfonso-Cristancho [États-Unis] ; Sean D. Sullivan [États-Unis]Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach
000089 (2013) Alfredo Adán [Espagne] ; Marina Mesquida [Espagne] ; Victor Llorenç [Espagne] ; Gerard Espinosa [Espagne] ; Blanca Molins [Espagne] ; Maria V. Hernández [Espagne] ; Laura Pelegrín [Espagne]Tocilizumab treatment for refractory uveitis-related cystoid macular edema
000102 (2011) Masahiko Suzuki [Japon] ; Keiichiro Nishida [Japon] ; Satoshi Soen [Japon] ; Hiromi Oda [Japon] ; Hiroshi Inoue [Japon] ; Atsushi Kaneko [Japon] ; Kenji Takagishi [Japon] ; Takaaki Tanaka [Japon] ; Tsukasa Matsubara [Japon] ; Naoto Mitsugi [Japon] ; Yuichi Mochida [Japon] ; Shigeki Momohara [Japon] ; Toshihito Mori [Japon] ; Toru Suguro [Japon]Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association
000105 (2012) M. Gallego-Galisteo ; A. Villa-Rubio ; E. Alegre-Del Rey [Espagne] ; E. Márquez-Fernández ; J. J. Ramos-BáezIndirect comparison of biological treatments in refractory rheumatoid arthritis
000113 (2005) Josef S. Smolen [Autriche] ; Kurt Redlich [Autriche] ; Jochen Zwerina [Autriche] ; Daniel Aletaha [Autriche] ; Günter Steiner [Autriche] ; Georg Schett [Autriche]Pro-inflammatory cytokines in rheumatoid arthritis
000143 (2012) Maxime Samson [France] ; Sylvain Audia [France] ; Nona Janikashvili [France] ; Marion Ciudad [France] ; Malika Trad [France] ; Jennifer Fraszczak [France] ; Paul Ornetti [France] ; Jean-Francis Maillefert [France] ; Pierre Miossec [France] ; Bernard Bonnotte [France]Brief Report: Inhibition of interleukin‐6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis
000147 (2010) Tamotsu Kamishima [Japon] ; Kazuhide Tanimura [Japon] ; Masato Shimizu [Japon] ; Megumi Matsuhashi [Japon] ; Jun Fukae [Japon] ; Yujiro Kon [Royaume-Uni] ; Hiromi Hagiwara [Japon] ; Akihiro Narita [Japon] ; Yuko Aoki [Japon] ; Naoki Kosaka [Japon] ; Tatsuya Atsumi [Japon] ; Hiroki Shirato [Japon] ; Satoshi Terae [Japon]Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger
000154 (2011) Atsushi Kaneko [Japon] ; Daihei Kida [Japon] ; Kiwamu Saito [Japon] ; Masami Tsukamoto [Japon] ; Tomotaro Sato [Japon]Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI
000169 (2015) Yanli Zhuang [États-Unis] ; Dick E. De Vries [Pays-Bas] ; Zhenhua Xu [États-Unis] ; Stanley J. Marciniak Jr. [États-Unis] ; Dion Chen [États-Unis] ; Francisco Leon [États-Unis] ; Hugh M. Davis [États-Unis] ; Honghui Zhou [États-Unis]Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach
000178 (2010) G. Dückers [Allemagne] ; T. Niehues [Allemagne]Die Bedeutung von Biologika bei der Therapie der SoJIA (Morbus Still)
000179 (2009) Masahiko Mihara [Japon] ; Yoshiyuki Ohsugi [Japon] ; Tadamitsu KishimotoEvidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti‐interluekin‐6 receptor antibody

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation
HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "results" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "results" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    results
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021